GMAB vs QDEL: fair value comparison
Genmab A/S and QuidelOrtho Corporation · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, GMAB currently sits closer to the top of our discount ranking. GMAB carries the stronger quality grade.
| GMAB | QDEL | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $28.68 | $17.71 |
| 12-month range | $25.45–$33.27 | $12.64–$31.25 |
| Sector rank | #45 of 113 Healthcare | #50 of 113 Healthcare |
| Quality grade | A | F |
| Momentum grade | — | B |
| Leverage | Low | Moderate |
| Margin trend | Contracting | Expanding |
| Revenue growth | Declining | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| DCF cross-check | Undervalued | — |
| 52-week position | The lower-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: GMAB fair value analysis · QDEL fair value analysis